Thrivent Financial for Lutherans
CAPR icon

Thrivent Financial for Lutherans’s Capricor Therapeutics CAPR Stock Holding History

Thrivent Financial for Lutherans’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,750
Closed -$54K – 2529
2020
Q4 		$54K Buy
+15,750
New +$68.3K ﹤0.01% 2450

Other funds holding CAPR

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TMC
Trellus Management Company Delray Beach, Florida $72.8M AUM 4.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Thrivent Financial for Lutherans's CAPR Position: Q1 2021 in Review

Thrivent Financial for Lutherans sold out of Capricor Therapeutics (CAPR) in Q1 2021, closing a stake of 15,750 shares — an estimated $54K sold.

Thrivent Financial for Lutherans first reported a position in CAPR in Q4 2020 and held it in 1 quarter. The position peaked at $54K in Q4 2020. 30 funds tracked by Wall St. Rank hold CAPR as of Q1 2021.

  • Thrivent Financial for Lutherans reported no remaining Capricor Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 15,750 Capricor Therapeutics shares in Q1 2021, an estimated $54K.
  • Thrivent Financial for Lutherans first reported a position in Capricor Therapeutics in Q4 2020 and held it in 1 quarter.
  • Thrivent Financial for Lutherans's Capricor Therapeutics position peaked at $54K in Q4 2020.
  • 30 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2021.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2021, filed 17 May 2021.